The primary tumors of the pleura are usually examined under two headings: diffuse and localized tumors. In the localized form, there is no relationship with asbestosis (1). Localized fibrous tumors were previously known by names such as benign mesothelioma, submesothelial fibroma and localized fibrous mesothelioma. Today, they are usually referred as localized fibrous tumors (2). These tumors c...

Multicystic benign mesothelioma (MBM) is a rare peritoneal pathology typically affecting women in reproductive age. Though MBM is considered benign, these lesions are prone to recurrence and their growth could be modulated by the presence of oestrogen receptors. Acute presentation of MBM is still very rare in pregnancy and management options are not established. We describe a case of MBM presen...

Two promising ancillary tests used in the diagnosis of mesothelioma include GLUT-1 immunohistochemical analysis and fluorescence in situ hybridization (FISH) testing for the p16 deletion. This study compared the diagnostic usefulness of p16 FISH and GLUT-1 immunohistochemical analysis in the diagnosis of mesothelial proliferations in 158 cases with a diagnosis of benign (45.4%), atypical (10.4%...

Malignant mesothelioma is an asbestos-induced, aggressive tumour with limited treatment options and very poor outcome. Currently, there are no tumour biomarkers in widespread clinical use for this disease. Soluble mesothelin is the most intensively investigated mesothelioma biomarker and has been approved by the US FDA primarily as a tool for monitoring patient response and progression. Mesothe...

A n estimated 150 000 patients develop a pleural effusion each year in the UK. Establishing the aetiology of pleural effusions can be challenging as they can be associated with over 50 systemic or pulmonary disorders. Exudative pleural fluids arise from plasma extravasation and contain proteins and cells from the systemic circulation, as well as those released locally from the pleura. This mili...